The Korean Journal of Medicine

  • 제80권4호
  • /
  • Pages.386-392
  • /
  • 2011
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지

외과적 치료의 최신 성적

Surgical Results of Pancreatic Neuroendocrine Tumors

  • 장진영 (서울대학교 의과대학 외과학교실)
  • Jang, Jin-Young (Department of Surgery, Seoul National University College of Medicine)
  • 발행 : 2011.04.01
⟨ 이전 논문 다음 논문 ⟩

초록

Pancreatic neuroendocrine tumor (PNET) is a rare, but attracts clinician' attention due to its clinicopathologically peculiar features compared to conventional pancreatic tumor originated from duct or acina. Surgical resection has been the main treatment tool for PNET. The method of resection must be tailored considering tumor biology and patient' condition. Although most of benign PNET can be cured by enucleation or limited resection, conventional resection should be considered if tumor is located near to main pancreatic duct or suspected as malignant lesions. In contrast to other pancreatic malignancies, surgery has major role to increase the survival by debulking operation or metastatectomy even in advanced stage. Although the surgical indication of liver transplantation must be elucidated, the overall survival after liver transplantation in hepatic metastasis is not superior to other conventional treatment. With development of new diagnosis and therapeutic agents using tumor biology, the aggressive treatment with surgery and medical treatment could improve the survival of patients with PNET.

키워드

참고문헌

  1. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753-781. https://doi.org/10.1016/j.bpg.2005.06.002
  2. Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-3500. https://doi.org/10.1245/s10434-007-9566-6
  3. Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg 2010;14:541-548. https://doi.org/10.1007/s11605-009-1115-0
  4. Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 2008;247:490-500. https://doi.org/10.1097/SLA.0b013e31815b9cae
  5. 김송철, 장혁재. 췌장의 내분비 종양. 간담췌외과학. 2nd ed. 서울: 의학문화사, 2006:884-893.
  6. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatinreceptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53-R73. https://doi.org/10.1677/ERC-09-0078
  7. Hashimoto LA, Walsh RM. Preoperative localization of insulinomas is not necessary. J Am Coll Surg 1999;189:368-373. https://doi.org/10.1016/S1072-7515(99)00163-5
  8. Abood GJ, Go A, Malhotra D, Shoup M. The surgical and systemic management of neuroendocrine tumors of the pancreas. Surg Clin North Am 2009;89:249-266. https://doi.org/10.1016/j.suc.2008.10.001
  9. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005;19:783-798. https://doi.org/10.1016/j.bpg.2005.05.008
  10. Yedibela S, Reck T, Hohenberger W. Resection of liver metastases: goal, timing and results. Ther Umsch 2001;58:713-717. https://doi.org/10.1024/0040-5930.58.12.713
  11. Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 2007;245:273-281. https://doi.org/10.1097/01.sla.0000232556.24258.68
  12. Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995;46:395-411. https://doi.org/10.1146/annurev.med.46.1.395
  13. Norton JA. Gastrinoma: advances in localization and treatment. Surg Oncol Clin N Am 1998;7:845-861.
  14. Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998;17:389-400.
  15. Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 1994;31:77-156.
  16. Bilimoria KY, Tomlinson JS, Merkow RP, et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg 2007;11:1460-1467. https://doi.org/10.1007/s11605-007-0263-3
  17. Kent RB 3rd, van Heerden JA, Weiland LH. Nonfunctioning islet cell tumors. Ann Surg 1981;193:185-190. https://doi.org/10.1097/00000658-198102000-00010
  18. Evans DB, Skibber JM, Lee JE, et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 1993;114:1175-1181.
  19. Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130:1078-1085. https://doi.org/10.1067/msy.2001.118367
  20. Dralle H, Krohn SL, Karges W, Boehm BO, Brauckhoff M, Gimm O. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg 2004;28:1248-1260. https://doi.org/10.1007/s00268-004-7609-8
  21. Pederzoli P, Falconi M, Bonora A, et al. Cytoreductive surgery in advanced endocrine tumours of the pancreas. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S207-S212.
  22. Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006;84:196-211. https://doi.org/10.1159/000098012
  23. Celinski SA, Nguyen KT, Steel JL, et al. Multimodality management of neuroendocrine tumors metastatic to the liver. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 234.
  24. Dimou AT, Syrigos KN, Saif MW. Neuroendocrine tumors of the pancreas: what's new: highlights from the "2010 ASCO gastrointestinal cancers symposium": Orlando, FL, USA. January 22-24, 2010. JOP 2010;11:135-138.
  25. Khodjibekova M, Szyszko T, Singh A, Tait P, Rubello D, Al-Nahhas A. Treatment of primary and secondary liver tumours with selective internal radiation therapy. J Exp Clin Cancer Res 2007;26:561-570.
  26. O'Grady JG. Treatment options for other hepatic malignancies. Liver Transpl 2000;6(6 Suppl 2):S23-S29. https://doi.org/10.1053/jlts.2000.18687
  27. Le Treut YP, Gregoire E, Belghiti J, et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 2008;8:1205-1213. https://doi.org/10.1111/j.1600-6143.2008.02233.x
  28. Rosenau J, Bahr MJ, von Wasielewski R, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002;73:386-394. https://doi.org/10.1097/00007890-200202150-00012
  29. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl 2006;12:448-456. https://doi.org/10.1002/lt.20702
  30. Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol 2007;47:460-466. https://doi.org/10.1016/j.jhep.2007.07.004
  31. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401. https://doi.org/10.1007/s00428-006-0250-1
  32. National Cancer Data Base. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010:241-249.